Monitoring and improving hepatitis C health outcomes among people with hepatitis C

点击翻译按钮获取中文摘要

In Australia, hepatitis C is associated with considerable morbidity and mortality, costing $9.2 billion to the health care system. In the next year, side-effect prone hepatitis C therapies will be replaced with simple, tolerable, interferon-free therapies (cure >90%) that can reverse liver disease progression. My goal is to further develop my established research program in population-health related to HCV epidemiology, and therapeutic strategies, with a specific focus on PWID.